<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92110</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Bol'noy arterial'noy gipertoniey, ne priverzhennyy lecheniyu</article-title><trans-title-group xml:lang="ru"><trans-title>Больной артериальной гипертонией, не приверженный лечению</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fomin</surname><given-names>V. V</given-names></name><name xml:lang="ru"><surname>Фомин</surname><given-names>В. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Moiseev</surname><given-names>S. V</given-names></name><name xml:lang="ru"><surname>Моисеев</surname><given-names>С. В</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Saginova</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Сагинова</surname><given-names>Е. А</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клиника нефрологии, внутренних и профессиональных болезней им. Е.М.Тареева</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en"></institution></aff><aff><institution xml:lang="ru">ММА им. И.М.Сеченова</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2006-05-15" publication-format="electronic"><day>15</day><month>05</month><year>2006</year></pub-date><volume>8</volume><issue>5</issue><issue-title xml:lang="en">VOL 8, NO5 (2006)</issue-title><issue-title xml:lang="ru">ТОМ 8, №5 (2006)</issue-title><fpage>33</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2006, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2006, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2006</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/92110">https://consilium.orscience.ru/2075-1753/article/view/92110</self-uri><abstract xml:lang="ru"><p>Необходимость достижения контроля артериального давления (АД), подразумевающего поддержание его уровня на целевых значениях в течение всего периода между очередными приемами антигипертензивного препарата у всех пациентов, страдающих эссенциальной артериальной гипертонией (АГ), не вызывает сомнения. Обоснованность этой стратегии антигипертензивной терапии определяется прежде всего значительным снижением риска сердечно-сосудистых осложнений в той ситуации, когда уровень АД постоянно не превышает верхний предел целевого (140/90 мм рт. ст. для всех больных АГ).Повышение приверженности антигипертензивной терапии – один из наиболее реальных способов повышения ее эффективности. Очевидно, что добиться соблюдения рекомендаций можно только при сотрудничестве врача с пациентом, во многом достигающемся за счет подробного и вместе с тем доступного информирования последнего о цели лечения эссенциальной АГ, заключающейся в конечном итоге в увеличении продолжительности активной жизни. Минимизация выраженности нежелательных явлений, связанных с приемом антигипертензивных препаратов, сегодня вполне возможна за счет оптимизации режима их приема и подбора доз, а также тщательного учета противопоказаний к назначению определенного их класса, в том числе относительных. В свою очередь недостаточная приверженность антигипертензивной терапии приближает риск осложнений АГ у подобных пациентов к тем, кто вообще не получает лечения.</p></abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>антигипертензивная терапия</kwd><kwd>приверженность лечению</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Frohlich E.D. The necessity for recognition and treatment of patients with “mild” hypertension. J Am Coll Cardiol 1999; 34: 1369–77.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hajjar I, Kotchen T.A. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Wolf-Maier K, Cooper R.S, Kramer H. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Macedo M.E, Lima M.J, Silva A.O et al. Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens 2005; 23: 1661–6.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Brindel P, Hanon O, Dartigues J.F et al. Prevalence, awareness, treatment, and control of hypertension in the elderly: the Three City study. J Hypertens 2006; 24: 51–8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Borghi C, Dormi A, D'Addato S et al. Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. J Hypertens 2004; 22: 1707–16.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cuspidi C, Michev I, Lonati L et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens 2002; 16: 699–703.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Clause S.L, Hamilton R.A. Medicaid prescriber compliance with Joint National Committee VI Hypertension Treatment Guidelines. Ann Pharmacother 2002; 36: 1505–11.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Degli Esposti E, Di Martino M, Sturani A. Risk factors for uncontrolled hypertension in Italy. J Hum Hypertens 2004; 18: 207–13.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Фомин И.В., Мареев В.Ю., Фадеева И.П. и др. Истинная распространенность артериальной гипертонии и современное состояние гипотензивной терапии в Нижегородской области (данные регистра 1998 г.). Кардиология. 2000; 9: 33–7.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Агеев Ф.Т., Мареев В.Ю., Патрушева И.Ф. Правильно ли мы выбираем гипотензивный препарат в повседневной амбулаторной практике и как исправить эту ситуацию? (По результатам исследования в Московском городском кардиодиспансере и многоцентровых исследований ФЛАГ и ФАГОТ). Сердце. 2003; 2 (4): 185–9.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Беленков Ю.Н., Мареев В.Ю. Как мы лечим больных с сердечно - сосудистыми заболеваниями в реальной клинической практике. Тер. арх. 2003; 8: 5–11.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Garg J.P, Elliott W.J, Folker A et al. Resistant hypertension revisited: a comparison of two university - based cohorts. Am J Hypertens 2005; 18 (5 Pt. 1): 619–26.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Degli Esposti L, Degli Esposti E, Valpiani G et al. A retrospective, population - based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002; 24: 1347–57.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Wetzels G.E, Nelemans P, Schouten J.S, Prins M.H. Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens 2004; 22: 1849–55.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fodor G.J, Kotrec M, Bacskai K et al. Is interview a reliable method to verify the compliance with antihypertensive therapy? An international central - European study. J Hypertens 2005; 23: 1261–6.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Salas M, In't Veld B.A, van der Linden P.D et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther 2001; 70: 561–6.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Alam M.G, Barri Y.M. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am J Hypertens 2003; 16: 140–3.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Chapman R.H, Benner J.S, Petrilla A.A et al. Predictors of adherence with antihypertensive and lipid - lowering therapy. Arch Intern Med 2005; 165: 1147–52.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Schroeder K, Fahey T, Ebrahim S. How can we improve adherence to blood pressure - lowering medication in ambulatory care? Systematic review of randomized controlled trials. Arch Intern Med 2004; 164: 722–32.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Iskedjian M, Einarson T.R, Mac Keigan L.D et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta - analysis. Clin Ther 2002; 24: 302–16.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Chobanian A.V, Bakris G.L, Black H.R et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The JNC VI Report. JAMA 2003; 289: 2560–71.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии. Сердце. 2005; 4 (3): 120–6.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Schoberberger R, Janda M, Pescosta W, Sonneck G. The COMpliance Praxis Survey (COMPASS): a multidimensional instrument to monitor compliance for patients on antihypertensive medication. J Hum Hypertens 2002; 16: 779–87.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Akpa M.R, Agomuoh D.I, Odia O.J. Drug compliance among hypertensive patients in Port Harcourt, Nigeria. Niger J Med 2005; 14: 55–7.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Black H.R, Elliott W.J, Grandits G et al. Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region. J Hypertens 2005; 23: 1099–106.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Raji M.A, Kuo Y.F, Salazar J.A et al. Ethnic differences in antihypertensive medication use in the elderly. Ann Pharmacother 2004; 38: 209–14.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Riehle J.F, Lackland D.T, Okonofua E.C et al. Ethnic differences in the treatment and control of hypertension in patients with diabetes. J Clin Hypertens (Greenwich) 2005; 7: 445–54.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Lau D.S, Lee G, Wong C.C et al. Characterization of systemic hypertension in the San Francisco Chinese community. Am J Cardiol 2005; 96: 570–3.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Cheung B.M, Wong Y.L, Lau C. Queen Mary Utilization of Antihypertensive Drugs Study: side - effects of antihypertensive drugs. J Clin Pharm Ther 2005; 30: 391–9.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Zanchetti A, Hansson L, Menard J et al. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study for the HOT Study Group. J Hypertens 2001; 19: 819–25.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10–24.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Burchardt M, Burchardt T, Baer L et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000; 164: 1188–91.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65: 773–86.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Giuliano F.A, Leriche A, Jaudinot E.O et al. Prevalence of erectile dysfunction among 7689 patients with diabetes or hypertension, or both. Urology 2004; 64: 1196–201.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Roth A, Kalter-Leibovici O, Kerbis Y et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol 2003; 26: 25–30.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Aranda P, Ruilope L.M, Calvo C et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens 2004; 17: 139–45.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Wannemacher A.J, Schepers G.P, Townsend K.A. Antihypertensive medication compliance in a Veterans Affairs Healthcare System. Ann Pharmacother 2002; 36: 986–91.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Elliott W.J. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60: 582–8.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Opie L.H. Angiotensin converting enzyme inhibitors: the advance continues. 3d ed. UCT Press; 1999.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Visser L.E, Stricker B.H, van der Velden J et al. Angiotensin converting enzyme inhibitor associated cough: a population - based case - control study. J Clin Epidemiol 1995; 48: 851–7.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Mukae S, Itoh S, Aoki S et al. Association of polymorphisms of the renin - angiotensin system and bradykinin B2 receptor with ACE-inhibitor - related cough. J Hum Hypertens 2002; 16: 857–63.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Kostis J.B, Shelton B, Gosselin G et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 1996; 131: 350–55.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253–9.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Luque C.A, Vazquez Ortiz M. Treatment of ACE inhibitor - induced cough. Pharmacotherapy 1999; 19: 804–10.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Tenenbaum A, Grossman E, Shemesh J et al. Intermediate but not low doses of aspirin can suppress angiotensin - converting enzyme inhibitor - induced cough. Am J Hypertens 2000; 13: 776–82.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>David D, Jallad N, Germino F.W et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor - associated cough. Am J Ther 1995; 2: 806–13.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Zanchetti A, Crepaldi G, Bond M.G et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS – a randomized double - blind trial. Stroke 2004; 35: 2807–12.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Asselbergs F.W, Diercks G.F.H, Hillege H.L et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809–16.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Pitt B, Poole-Wilson P.A, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–7.</mixed-citation></ref></ref-list></back></article>
